ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)

被引：0
|
作者：
Mastikhina, L. [1 ]
Cope, S. [2 ]
Marshall, T. [3 ]
Maciel, D. [2 ]
Mojebi, A. [2 ]
Karampampa, K. [4 ]
Dhanda, D. [3 ]
机构：
[1] PRECISIONheor, Evidence Synth & Decis Modeling, Calgary, AB, Canada
[2] PRECISIONheor, Evidence Synth & Decis Modeling, Vancouver, BC, Canada
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Bristol Myers Squibb, Uxbridge, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO91
引用
收藏
页码：S30 / S31
页数：2
相关论文
共 50 条
  • [1] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos M.
    Sonneveld P.
    Manier S.
    Lam A.
    Roccia T.
    Schecter J.M.
    Cost P.
    Pacaud L.
    Poirier A.
    Tremblay G.
    Lan T.
    Valluri S.
    Kumar S.
    [J]. BMC Cancer, 24 (1)
  • [2] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [3] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [4] Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John Frederick
    Goss, Glenwood D.
    Fung-Kee-Fung, Michael
    Jonker, Derek J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] The relationship between overall survival (OS) and progression-free survival (PFS) in gastrointestinal stromal tumor (GIST).
    Stillman, Ipek Ozer
    Strand, Lauren N.
    Chang, Jane
    Mohamed, Ateesha F.
    Fahrbach, Kyle
    Freier, Katherine E. Tranbarger
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    M Hussein
    A S Swern
    D Weber
    [J]. Leukemia, 2011, 25 : 1620 - 1626
  • [7] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Hussein, M.
    Swern, A. S.
    Weber, D.
    [J]. LEUKEMIA, 2011, 25 (10) : 1620 - 1626
  • [8] Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)
    Stewart, D.
    Bosse, D.
    Ocana, A.
    Goss, G.
    Jonker, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1782 - S1782
  • [9] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
    Wani, Kashmira
    Gutta, Radhika
    Mittal, Aayush
    Jamil, Maria
    Springer, Kylie
    Kuriakose, Philip
    [J]. BLOOD, 2023, 142
  • [10] THE OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) OF HYPERPROGRESSIVE DISEASE (HDP) IN LUNG CANCER PATIENTS
    Oh, Youjin
    Djunadi, Trie Arni
    Chung, Liam Il-Young
    Lee, Soowon
    Hong, Timothy
    Shah, Zunairah
    Park, Joo Hee
    Yoon, Sung Mi
    Duan, Richard
    Chae, Young Kwang
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1468 - A1469
12345